



Evofosfamide and mTOR inhibitors



Supplementary Figure 1. Body weight change of evofosfamide in combination with mTOR inhibitors in the 786-O and Caki-1 xenograft model. Combination treatment in Concurrent Schedule and Delayed Schedule was tested. Animals were monitored daily and body weight change were quantified twice a week. Data are expressed as Mean \pm SEM of 10 animals per group. Evo, evofosfamide; Eve, everolimus; Tem, temsirolimus; CS, Concurrent Schedule; and DS, Delayed Schedule.



Supplementary Figure 2. Effect of mTOR inhibitor on phosphorylated mTOR protein (p-mTOR) expression detected by p-mTOR protein immunostaining. Rabbit polyclonal p-mTOR protein (Cell Signaling, 1:10) was used as a primary antibody. Everolimus and temsirolimus were used in the 786-O and Caki-1 xenografts, respectively. Evo, evofosfamide; and mTORi, mTOR inhibitor.